GC01.1
Glioblastoma and other βIII-tubulin overexpressing solid tumors
PreclinicalActive
Key Facts
Indication
Glioblastoma and other βIII-tubulin overexpressing solid tumors
Phase
Preclinical
Status
Active
Company
About GlioCure
GlioCure is a private, preclinical-stage biotech targeting glioblastoma and other solid tumors through a novel peptide platform. Its lead asset, GC01.1, is a βIII-tubulin-targeting peptide in late non-regulatory preclinical development, with three patent families supporting its pipeline. The company is led by an experienced bio-entrepreneur and a neuroscience researcher, having raised €3 million since inception to advance its neuro-oncology programs.
View full company profile